{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:32:41Z","timestamp":1790713961043,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The primary clinical approach for diffuse large B-cell lymphoma (DLBCL) in recent decades has predominantly relied on chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as the cornerstone. However, given the highly heterogeneous nature of DLBCL, &amp;gt;30% of patients are prone to relapse and may even exhibit resistance to treatment. Antibody-drug conjugate (ADC) therapies have demonstrated significant advancements in clinical trials targeting DLBCL, thereby indicating a promising direction for its management. By leveraging the inherent modifiability of DNA nanostructures and the affinity of doxorubicin for DNA, we used a combination of rituximab-based R-CHOP scheme and DNA tetrahedra to fabricate antibody-DNA nanostructure conjugate (ADNC). The rituximab-tetrahedron-doxorubicin conjugate (RTD) studied in our research has been validated through in vitro cellular experiments and subcutaneous tumor models. The RTD demonstrated a robust antitumor effect in vitro, significantly exceeding the combined effects of rituximab and doxorubicin by &amp;gt;50-fold. Furthermore, confirmation from a subcutaneous tumor model substantiated the potent antitumor efficacy of RTD while successfully mitigating cardiotoxicity and hematotoxicity associated with doxorubicin. ADNC effectively facilitates the binding of rituximab and doxorubicin in the R-CHOP regimen, offering novel prospects for the development of next-generation ADC drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017118","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T20:01:14Z","timestamp":1759262474000},"page":"6549-6562","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Antibody-DNA nanostructure conjugates integrate doxorubicin and rituximab to enhance therapeutic efficacy for DLBCL"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3346-4868","authenticated-orcid":false,"given":"Zuguang","family":"Xia","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8510-5044","authenticated-orcid":false,"given":"Jiazhen","family":"Cao","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhu","family":"Li","sequence":"additional","affiliation":[{"name":"4Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Wu","sequence":"additional","affiliation":[{"name":"4Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ren","sequence":"additional","affiliation":[{"name":"4Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Sheng","sequence":"additional","affiliation":[{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"5Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"6Institute of Pathology, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7318-8284","authenticated-orcid":false,"given":"Chengxun","family":"Li","sequence":"additional","affiliation":[{"name":"7Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-740X","authenticated-orcid":false,"given":"Shengjie","family":"Li","sequence":"additional","affiliation":[{"name":"4Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"9","key":"2025122308561424400_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2025122308561424400_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms","volume":"134","author":"Wang","year":"2020","journal-title":"Chin Med J"},{"issue":"5","key":"2025122308561424400_bib3","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.3324\/haematol.2014.120113","article-title":"Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma","volume":"100","author":"Jordheim","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"2025122308561424400_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025122308561424400_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025122308561424400_bib6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3390\/cancers14061453","article-title":"DLBCL 1L-what to expect beyond R-CHOP?","volume":"14","author":"Stegemann","year":"2022","journal-title":"Cancers"},{"issue":"24","key":"2025122308561424400_bib7","first-page":"7190","article-title":"Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs","volume":"62","author":"Sapra","year":"2002","journal-title":"Cancer Res"},{"issue":"6","key":"2025122308561424400_bib8","doi-asserted-by":"crossref","first-page":"1602267","DOI":"10.1002\/smll.201602267","article-title":"Sortase A-generated highly potent anti-CD20-MMAE conjugates for efficient elimination of B-lineage lymphomas","volume":"13","author":"Pan","year":"2017","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"issue":"7","key":"2025122308561424400_bib9","doi-asserted-by":"crossref","first-page":"10496","DOI":"10.1021\/acsnano.2c01382","article-title":"Geometry of a DNA nanostructure influences its endocytosis: cellular study on 2D, 3D, and in vivo systems","volume":"16","author":"Rajwar","year":"2022","journal-title":"ACS nano"},{"issue":"30","key":"2025122308561424400_bib10","doi-asserted-by":"crossref","first-page":"e2311690","DOI":"10.1002\/smll.202311690","article-title":"Cholesterol-modified DNA nanostructures serve as effective non-viral carriers for delivering siRNA to the kidneys to prevent acute kidney injury","volume":"20","author":"Li","year":"2024","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"issue":"1","key":"2025122308561424400_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tips.2022.10.003","article-title":"Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity","volume":"44","author":"Wu","year":"2023","journal-title":"Trends Pharmacol Sci"},{"issue":"36","key":"2025122308561424400_bib12","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"2025122308561424400_bib13","doi-asserted-by":"crossref","first-page":"e22998","DOI":"10.1002\/bip.22998","article-title":"DNA-doxorubicin interaction: New insights and peculiarities","volume":"107","author":"Silva","year":"2017","journal-title":"Biopolymers"},{"key":"2025122308561424400_bib14","doi-asserted-by":"crossref","first-page":"113613","DOI":"10.1016\/j.jconrel.2025.113613","article-title":"Antibody-DNA nanostructure conjugate enables targeted delivery of gemcitabine to tumor and improves the anti-tumor efficacy","volume":"381","author":"Li","year":"2025","journal-title":"J Control Release"},{"issue":"18","key":"2025122308561424400_bib15","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2015-09-672352","article-title":"Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2025122308561424400_bib16","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1039\/C8CP06752J","article-title":"Fluorescence correlation spectroscopy for multiple-site equilibrium binding: a case of doxorubicin-DNA interaction","volume":"21","author":"Zhang","year":"2019","journal-title":"Phys Chem Chem Phys"},{"issue":"1","key":"2025122308561424400_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13046-019-1446-y","article-title":"Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma","volume":"38","author":"Jiang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2025122308561424400_bib18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/cancers15041298","article-title":"Sex- and female age-dependent differences in gene expression in diffuse large B-cell lymphoma-possible estrogen effects","volume":"15","author":"Huang","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"2025122308561424400_bib19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"issue":"1","key":"2025122308561424400_bib20","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/s41467-021-23071-6","article-title":"Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance","volume":"12","author":"Giddings","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"2025122308561424400_bib21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3390\/cells12111462","article-title":"Aberrant DNA methylation, expression, and occurrence of transcript variants of the ABC transporter ABCA7 in breast cancer","volume":"12","author":"Zappe","year":"2023","journal-title":"Cells"},{"issue":"1","key":"2025122308561424400_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00280-013-2176-z","article-title":"Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues","volume":"72","author":"Patel","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2025122308561424400_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs","volume":"64","author":"An","year":"2024","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2025122308561424400_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.7150\/ijbs.65258","article-title":"Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death","volume":"18","author":"Kong","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2025122308561424400_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-022-04400-y","article-title":"Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells","volume":"89","author":"Nicoletto","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2025122308561424400_bib26","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/jcm13071929","article-title":"New insights into first-line therapy in diffuse large B-cell lymphoma: are we improving outcomes?","volume":"13","author":"Abrisqueta","year":"2024","journal-title":"J Clin Med"},{"issue":"9","key":"2025122308561424400_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/17474086.2022.2124156","article-title":"Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP","volume":"15","author":"Hill","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"20","key":"2025122308561424400_bib28","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025122308561424400_bib29","first-page":"426","article-title":"T-DXd is effective after T-DM1","volume":"20","author":"Sidaway","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2025122308561424400_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"2025122308561424400_bib31","doi-asserted-by":"crossref","first-page":"1483617","DOI":"10.3389\/fimmu.2024.1483617","article-title":"Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression","volume":"15","author":"Nguyen","year":"2024","journal-title":"Front Immunol"},{"key":"2025122308561424400_bib32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-11-0154","article-title":"Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives","volume":"9","author":"Bezombes","year":"2011","journal-title":"Mol Cancer Res : MCR"},{"issue":"11","key":"2025122308561424400_bib33","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1007\/s11095-007-9369-2","article-title":"Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance","volume":"24","author":"Chen","year":"2007","journal-title":"Pharm Res"},{"issue":"1","key":"2025122308561424400_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/taap.1994.1232","article-title":"In vitro effects of hydroquinone, benzoquinone, and doxorubicin on mouse and human bone marrow cells at physiological oxygen partial pressure","volume":"129","author":"Colinas","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"issue":"8","key":"2025122308561424400_bib35","doi-asserted-by":"crossref","first-page":"e2210267","DOI":"10.1002\/adma.202210267","article-title":"Tetrahedral DNA nanostructure with interferon stimulatory DNA delivers highly potent toxins and activates the cGAS-STING pathway for robust chemotherapy and immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv Mater"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6549\/2475808\/blooda_adv-2025-017118-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6549\/2475808\/blooda_adv-2025-017118-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:56:27Z","timestamp":1766498187000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6549\/547529\/Antibody-DNA-nanostructure-conjugates-integrate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":35,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017118","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,15]]}}}